Today’s valuation suggests the Street really isn’t buying into much of any of that. Not only do the shares trade below my DCF-based estimate of fair value, they also trade well below where med-techs …
More ViewRay Climbing A Steep Hill As It Tries To Disrupt The Radiation Oncology Market Videos